Table 1.
Clone | CD4 | CD8 | TCRVβ | Inhibition (%)a) |
---|---|---|---|---|
S1A4 as stimulating cells | ||||
1D1 | − | + | 1 | 17 |
1F3 | − | + | 2 | 57 |
1E5 | − | + | 13.1 | 47 |
2B2 | − | + | 13.1 | 44 |
1B8 | − | + | 14 | 18 |
1A5 | − | + | 22 | 58 |
1A2 | − | + | n.i. | 18 |
1B1 | − | + | n.i. | 59 |
1C3 | − | + | n.i. | 17 |
1C4 | − | + | n.i. | 39 |
1D7 | − | + | n.i. | 24 |
1F8 | − | + | n.i. | 51 |
2B5 | − | + | n.i. | 45 |
2B6 | − | + | n.i. | 44 |
S2B5 as stimulating cells | ||||
1A7 | − | + | 1 | 18 |
1C6 | − | + | 1 | 36 |
1D7 | − | + | 1 | 28 |
1F1 | − | + | 1 | 5 |
1B1 | − | + | 5 | 1 |
1C7 | − | + | 5.1 | 41 |
1E7 | +b) | + | 5.1 | 5 |
1B7 | − | + | 14 | 54 |
1B3 | − | + | 17 | 56 |
1C8 | − | + | 17 | 47 |
1C4 | − | + | 21.3 | 43 |
1E2 | − | + | 21.3 | 45 |
1A5 | − | + | 22 | 36 |
1A2 | − | + | n.i. | 37 |
1A3 | − | + | n.i. | 9 |
1A8 | + | − | n.i. | 7 |
1B4 | − | + | n.i. | 26 |
1B6 | − | + | n.i. | 8 |
1B8 | − | + | n.i. | 55 |
1C1 | − | + | n.i. | 17 |
1C2 | − | + | n.i. | 45 |
1D4 | − | + | n.i. | 48 |
1E1 | − | + | n.i. | 43 |
1E3 | − | + | n.i. | 34 |
1E5 | − | + | n.i. | 34 |
1E6 | − | + | n.i. | 44 |
1E8 | − | + | n.i. | 66 |
1F4 | − | + | n.i. | 3 |
1F5 | − | + | n.i. | 28 |
Percentage suppression of S2B5 cell viability at E/T ratio of 1:1 assessed by MTS assay.
Eight-seven percent of 1E7 cells are also CD8+; n.i., not identified.